{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:15:42Z","timestamp":1790709342015,"version":"4.1.0"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circ: Heart Failure"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>\n                      Transthyretin amyloidosis with cardiomyopathy is a progressive, fatal disease characterized by deposition of extracellular misfolded transthyretin (TTR) in the myocardium. Eplontersen is an N-acetylgalactosamine ligand\u2013conjugated antisense oligonucleotide targeting hepatocyte\n                      <jats:italic toggle=\"yes\">TTR<\/jats:italic>\n                      messenger RNA to reduce the production of circulating TTR.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>CARDIO-TTRansform is a Phase 3, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of eplontersen in transthyretin amyloidosis with cardiomyopathy. Key inclusion criteria include histological evidence of amyloid deposits or grade 2 to 3 cardiac uptake on cardiac scintigraphy in the absence of plasma cell dyscrasia, New York Heart Association class I\u2013III, and end-diastolic interventricular septum thickness &gt;12 millimeters. Participants were randomized 1:1 to receive eplontersen 45 mg or placebo, administered subcutaneously every 4 weeks for up to 140 weeks, followed by a 20-week post-treatment evaluation period or open-label extension. Participants received locally available standard of care, including unrestricted use of TTR stabilizers. The primary end point is a composite of cardiovascular mortality and recurrent clinical cardiovascular events through 140 weeks. Secondary end points, in order of testing hierarchy, include changes from baseline in 6-minute walk distance and Kansas City Cardiomyopathy Questionnaire overall summary score, recurrent cardiovascular events, all-cause mortality, the primary end point in the patient subgroup receiving stabilizers at baseline, and cardiovascular mortality. Echocardiography was performed in all participants, with cardiovascular magnetic resonance imaging and technetium scintigraphy in a subset.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>CARDIO-TTRansform is fully enrolled, with 1432 randomized participants who were dosed with study drug or placebo. As the largest transthyretin amyloidosis with cardiomyopathy study to date, it will evaluate whether eplontersen improves cardiovascular outcomes in patients receiving locally available standard of care, including TTR stabilizers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>REGISTRATION:<\/jats:title>\n                    <jats:p>\n                      URL:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\">https:\/\/www.clinicaltrials.gov<\/jats:ext-link>\n                      ; Unique identifier: NCT04136171. URL:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ClinicalTrialsRegister.eu\">http:\/\/ClinicalTrialsRegister.eu<\/jats:ext-link>\n                      ; Unique identifier: EudraCT number 2019-002835-27.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/circheartfailure.126.014205","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T09:33:14Z","timestamp":1778319194000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy"],"prefix":"10.1161","volume":"19","clinical-trial-number":[{"clinical-trial-number":"nct04136171","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6390-6526","authenticated-orcid":true,"given":"Ahmad","family":"Masri","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, Oregon Health and Sciences University, Portland (A.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1622-0732","authenticated-orcid":true,"given":"Francesco","family":"Cappelli","sequence":"additional","affiliation":[{"name":"Tuscan Regional Amyloidosis Center, Department of Clinical and Experimental Medicine, University Hospital Careggi, Florence, Italy (F.C.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot K.","family":"Davis","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of British Columbia, Vancouver, Canada (M.K.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9233-9831","authenticated-orcid":true,"given":"Marianna","family":"Fontana","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital, United Kingdom (M.F., J.D.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5470-2257","authenticated-orcid":true,"given":"Pablo","family":"Garcia-Pavia","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV and Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain (P.G.-P.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6174-9232","authenticated-orcid":true,"given":"Julian D.","family":"Gillmore","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital, United Kingdom (M.F., J.D.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Hanna","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Cleveland Clinic, OH (M.H.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7468-700X","authenticated-orcid":true,"given":"Laura","family":"Obici","sequence":"additional","affiliation":[{"name":"Amyloidosis Research and Treatment Centre, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy (L.O.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3698-9597","authenticated-orcid":true,"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Boston, MA (S.D.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8210-6401","authenticated-orcid":true,"given":"Brett W.","family":"Sperry","sequence":"additional","affiliation":[{"name":"Saint Luke\u2019s Mid America Heart Institute, Kansas City, MO (B.W.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2011-8201","authenticated-orcid":true,"given":"Nobuhiro","family":"Tahara","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, Kurume University School of Medicine, Japan (N.T.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4853-2236","authenticated-orcid":true,"given":"M\u00e1rcia","family":"Waddington-Cruz","sequence":"additional","affiliation":[{"name":"Centro de Paramiloidose Ant\u00f4nio Rodrigues de Mello (CEPARM), Amyloidosis Center, University Hospital, Federal University of Rio de Janeiro, Brazil (M.W.\u2013C.)."},{"name":"Amyloidosis Center, Complexo Hospitalar Am\u00e9ricas-Samaritano-Vit\u00f3ria, Rio de Janeiro, Brazil (M.W.\u2013C.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnt V.","family":"Kristen","sequence":"additional","affiliation":[{"name":"Amyloidosis Center, University of Heidelberg, Germany (A.V.K.)."},{"name":"Cardiovascular Center Darmstadt, Germany (A.V.K.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3329-2033","authenticated-orcid":true,"given":"Rodney H.","family":"Falk","sequence":"additional","affiliation":[{"name":"Harvard Medical School and Brigham and Women\u2019s Hospital, Boston, MA (R.H.F.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5655-8201","authenticated-orcid":true,"given":"Sanjiv J.","family":"Shah","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5481-2122","authenticated-orcid":true,"given":"Jose","family":"Nativi-Nicolau","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Jacksonville, FL (J.N.-N.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Viney","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc., Carlsbad, CA (N.J.V., Q.Y., S.T.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Yang","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc., Carlsbad, CA (N.J.V., Q.Y., S.T.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jersey","family":"Chen","sequence":"additional","affiliation":[{"name":"Late-Stage Clinical Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, MA (J.C.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9834-9494","authenticated-orcid":true,"given":"Sotirios","family":"Tsimikas","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc., Carlsbad, CA (N.J.V., Q.Y., S.T.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5400-5008","authenticated-orcid":true,"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[{"name":"Columbia University Irving Medical Center, New York, NY (M.S.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70246-0"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00334-4"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.04.003"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.0442"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0065-3233(08)60321-6"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/PL00000791"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12509-8"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40119-023-00344-3"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.038169"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12237250"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.09.004"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2024.10.011"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1695"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805689"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305434"},{"key":"e_1_3_3_17_2","volume-title":"Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis). Prescribing information","year":"2025","unstructured":"Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis). Prescribing information. Pfizer, 2025. Accessed December 16, 2025. https:\/\/www.fda.gov\/media\/126283\/download"},{"key":"e_1_3_3_18_2","volume-title":"Attruby (acoramidis). Prescribing information","year":"2025","unstructured":"Attruby (acoramidis). Prescribing information. BridgeBio Pharma, 2025. Accessed December 16, 2025. https:\/\/attruby.com\/attruby-prescribing-information.pdf"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716793"},{"key":"e_1_3_3_20_2","volume-title":"Wainua (eplontersen). Prescribing information","year":"2025","unstructured":"Wainua (eplontersen). Prescribing information. Ionis Pharmaceuticals and AstraZeneca, 2025. Accessed December 16, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda docs\/label\/2023\/217388s000lbl.pdf"},{"key":"e_1_3_3_21_2","volume-title":"Onpattro (patisiran). Prescribing information","year":"2025","unstructured":"Onpattro (patisiran). Prescribing information. Alnylam Pharmaceuticals, 2025. Accessed December 16, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210922s000lbl.pdf"},{"key":"e_1_3_3_22_2","volume-title":"Amvuttra (vutrisiran). Prescribing information","year":"2025","unstructured":"Amvuttra (vutrisiran). Prescribing information. Alnylam Pharmaceuticals, 2025. Accessed December 16, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215515s006lbl.pdf"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303765"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.125.077304"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409134"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx960"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.18688"},{"key":"e_1_3_3_28_2","volume-title":"Wainzua (eplontersen). Summary of product characteristics","year":"2025","unstructured":"Wainzua (eplontersen). Summary of product characteristics. Ionis pharmaceuticals and AstraZeneca, 2025. Accessed December 16, 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/wainzua-epar-product-information_en.pdf"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2023.11.016"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13154"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.6.2375"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.033502"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/1467-9868.00259"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1214\/aos\/1176345976"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2021.02.035"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.060852"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2300757"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-020-00183-7"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.11.023"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2020.06.007"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0158"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.04.011"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3354"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2023.05.004"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2018.0753"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114196"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa689"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31009-1"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2016.0650"}],"container-title":["Circulation: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCHEARTFAILURE.126.014205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T18:00:41Z","timestamp":1782064841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCHEARTFAILURE.126.014205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1161\/CIRCHEARTFAILURE.126.014205"],"URL":"https:\/\/doi.org\/10.1161\/circheartfailure.126.014205","relation":{},"ISSN":["1941-3289","1941-3297"],"issn-type":[{"value":"1941-3289","type":"print"},{"value":"1941-3297","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"2026-05-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}